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Abstract
Objective—Examine the relationship between antibodies to 25 oral bacteria and pancreatic
cancer risk in a prospective cohort study.
Design—We measured antibodies to oral bacteria in prediagnosis blood samples from 405
pancreatic cancer cases and 416 matched controls, nested within the European Prospective
Investigation into Cancer and Nutrition study (EPIC). Analyses were conducted using conditional
logistic regression and additionally adjusted for smoking status and body mass index.
Results—Individuals with high levels of antibodies against Porphyromonas gingivalis ATTC
53978, a pathogenic periodontal bacteria, had a 2-fold higher risk of pancreatic cancer than
individuals lower levels of these antibodies (odds ratio [OR], 2.14; 95% confidence interval [CI],
1.05–4.36; >200 ng/ml vs ≤200 ng/ml). To explore the association with commensal (non-
pathogenic) oral bacteria, we performed a cluster analysis and identified 2 groups of individuals,
based on their antibody profiles. A cluster with overall higher levels of antibodies had a 45%
lower risk of pancreatic cancer than a cluster with overall lower levels of antibodies (OR, 0.55;
95% CI, 0.36–0.83).
Conclusion—Periodontal disease might increase the risk for pancreatic cancer. Moreover,
increased levels of antibodies against specific commensal oral bacteria, which can inhibit growth
of pathogenic bacteria, might reduce the risk of pancreatic cancer. Studies are needed to determine
whether oral bacteria have direct effects on pancreatic cancer pathogenesis or serve as markers of
the immune response.
Keywords
infection; oral bacteria; pancreatic cancer; periodontal disease
INTRODUCTION
Each year, approximately 40,000 Americans die of cancer of the pancreas, making
pancreatic cancer the fourth most common cause of cancer-related mortality.1 Pancreatic
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cancer is one of the most rapidly fatal diseases, with fewer than half of patients surviving
past 6 months from diagnosis. Detection of pancreatic cancer at early stages could increase
survival; however, no biomarker currently has sufficient sensitivity and specificity for
screening of pancreatic cancer at the population level. Consequently, primary prevention of
pancreatic cancer is of particular importance in reducing the burden of this malignancy.
A positive association between periodontal disease and pancreatic cancer was observed in a
prospective cohort study of men health professionals.2 In this study, men reporting a
positive history of periodontal disease had a 64% higher risk of pancreatic cancer compared
with those reporting no periodontal disease; among never smokers, a 2-fold increase in
pancreatic cancer risk was observed (RR = 2.09, 95% CI = 1.18–3.71), ruling out the
possibility that the overall association was confounded by smoking. Other studies reported
similar findings between periodontal disease3, 4 or tooth loss5 and pancreatic cancer.
The role of bacteria in pancreatic diseases etiology or tumor development has been
suggested by multiple approaches. Using molecular methods, Helicobacter genus-specific
DNA (but not H. pylori species-specific DNA) was identified in pancreatic cancer tissues,6
while a positive association between Helicobacter pylori infection and pancreatic cancer has
been reported in several studies.7 Using culture methods, the microbiota isolated from the
pancreas had similarities to oral microbiota, particularly in the case of pancreatitis.8–11
Bacteria reaching the pancreatic tissues by dissemination has been documented in both
animal model and human subjects.9, 12, 13 Additionally, multiple observations have shown
that oral microbiota overlap with the digestive tract microbiota, providing multiple avenues
for dissemination in dysbiosis.14–17. In a recent retrospective case-control study, oral
bacteria measure in saliva were associated with pancreatic cancer.18
We undertook this study to further investigate the association between periodontal bacteria
and pancreatic cancer risk. Our a priori hypothesis (NIH R21 grant) was that antibodies to
three periodontal pathogens (Porphyromonas gingivalis, Tannerella forsythia, and
Aggregatibacter actinomycetemcomitans) are positively associated with pancreatic cancer
risk. We measured antibody levels to 25 oral bacteria, including strains that are elevated in
patients with chronic periodontitis, in plasma samples collected prior to disease onset in a
large European cohort study. This is the first study to examine antibodies to oral bacteria in
relation to pancreatic cancer risk.
MATERIALS AND METHODS
Study Population
The European Prospective Investigation into Cancer and Nutrition (EPIC) includes 519,978
participants, mostly aged 35–70 years, who were recruited in 23 centers within 10 European
countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain,
Sweden, and the United Kingdom) between 1992 and 2000. Detailed descriptions of the
study design, population, and baseline data collection of the cohort can be found in previous
report.19 Each participant provided informed consent. The local ethical review committees
approved the EPIC cohort study as well as the current project.
Blood Sample Collection and Storage
Collection of blood samples was obtained from 385,747 EPIC study participants. In all but
three countries (Denmark, Norway and Sweden), blood samples were collected based on a
standardized protocol and aliquoted in plastic straws (plasma, serum, erythrocytes, and buffy
coat for DNA). The aliquoted specimens were then stored in a central biorepository (IARC,
France) in liquid nitrogen (−196°C). In Norway the biological samples were collected in
twenty 0.5 ml plastic straws; 12 of the 16 plasma and two of the four buffy coat samples
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were shipped to IARC for storage in the central repository. In Sweden, all samples were
stored locally in freezers at −80°C and in Denmark in nitrogen vapour (−150°C).
Pancreatic Cancer Ascertainment
In seven of the participating countries (Denmark, Italy, the Netherlands, Norway, Spain,
Sweden, and the United Kingdom), follow-up of cancer cases is based on population cancer
registries. In France, Germany, Greece, and Naples (one center in Italy), a combination of
methods are used for follow-up and cancer ascertainment, including health insurance
records, cancer and pathology registries, and active follow-up through study subjects and
their next-of-kin. In all EPIC centers, data on vital status were collected from mortality
registries at the regional or national level, and combined with health insurance data (France)
or data collected by active follow-up (Greece). The percentage of subjects lost to follow-up
was 1.6% (loss is due to emigration, study withdrawal, or nonresponse in active follow-up
centers). Cancer incidence data are coded according to International Classification of
Diseases-Oncology 2nd edition and mortality data according to the International
Classification of Diseases 10th edition (ICD-10). Incidence cases of exocrine pancreatic
cancer reported during the study period were eligible for selection into this study. We
excluded participants who had other malignant tumors preceding the diagnosis of pancreatic
cancer, except for non-melanoma skin cancer. We identified 578 incident cases of pancreas
cancer that were coded according to ICD-10 (C25.0–25.3, 25.7–25.9); 468 of these cases
had blood specimens available. For each case, one control subject was selected (alive and
free of cancer at the time that the index case was diagnosed) using an incident density
sampling procedure. Matching characteristics consisted of: study center, sex, age at blood
collection, date and time of blood collection, fasting, and exogenous hormone use (women
only). For efficiency purposes matching was conducted for several planned cohort analyses
simultaneously; matching factors were selected with consideration of all analyses. Due to
insufficient volume or assay failure, the final dataset consisted of 405 cases and 416 control
subjects.
Antibody detection
All samples were de-identified and blinded to case-control status. Samples were sent to the
laboratory in matched pairs so that assays were consistently conducted on the same day for
each pair; however, the pairs were not kept in the same order (e.g., case-control; case-
control; control-case) to maintain blinding. The presence of antibodies in the plasma
samples against a pre-selected panel of whole-cell formalin fixed bacterial antigen was
tested using an immunoblot array.20 This method has the advantage of using a very small
amount of primary sample (less than 10µl). Bacterial strain selection was based on prior
detection in pancreatic tissues8–11 and known serotypes for Porphyromonas gingivalis
(ATCC 33277 [also known as strain 381], serotype a; ATCC 53978 [also known as the
capsulated strain W50], serotype b),21, 22 and Aggregatibacter actinomycetemcomitans
(ATCC 29523, serotype a; ATCC 43718, serotype b)23(see Table 2 for full list).
On a subset of the case and control subjects (n=532) replicate measurements of each
bacterial strain were performed (Supplemental Table 1). These were averaged for the overall
analysis and percent concordance was calculated among this subset of subjects for each
bacterial strain, in the following ranges of human IgG (ng/ml) antibody levels: 0–7.5; 7.6–
50; 50–200; >200 (respectively: no signal detected and to the lower detection limit of 7.5;
(>7.5–<50 ng/ml) lower range of the fitted reference curve; within the reference curve; and
higher end of the fitted reference curve to saturation). Percent concordance was found to be
good for all bacterial strains, ranging from 0.67 to 0.84 (Supplemental Table 1).
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Statistical Analysis
Differences between cases and controls across baseline characteristics were assessed by
paired t-tests (continuous variables) or by McNemar’s test (categorical variables).
Continuous measurements of the IgG antibody levels were log transformed to achieve
approximate normality.
To assess the association between individual bacterial strains suspected to be periodontal
pathogens and pancreatic cancer, we created four categories for the human IgG (ng/ml)
based on the quantitative results from the immunoassays (ranges of human IgG [ng/ml]
antibody levels: no signal detected and to the lower detection limit of 7.5; lower range of the
fitted reference curve (>7.5-<50 ng/ml); within the reference curve (50–200 ng/ml); higher
end of the fitted reference curve to saturation >200 ng/ml). We considered values above 200
ng/ml as seropositive and conducted the main analysis for the pathogens of interest as a
dichotomous variable comparing values above to below 200 ng/ml.
Potential confounding effects of factors other than those controlled for by matching (i.e.,
BMI, waist circumference, current and past tobacco smoking, and diabetes) were examined
by assessing the association of these factors with pancreatic cancer risk. We retained
smoking and BMI in all multivariate models; none of the other variables changed the
logistic β estimate by more than 10% (individually or when included simultaneously).
Subjects were defined as diabetics if they self-reported the condition in the baseline
questionnaire at recruitment. Analyses using unconditional regression models controlling for
matching factors led to similar results; we present results for the conditional regression
analyses.
To avoid multiple comparison issues when examining the measured oral bacteria antibodies
for which we did not have strong a priori hypotheses (i.e., the non-pathogenic periodontal
strains), we used an exploratory analysis to identify groups of people with similar levels of
oral antibodies (using all 25 measured strains). The cluster analysis was performed in R
using the MCLUST procedure.24 We retained two clusters based on optimal clustering
examining the BIC scores (for more details on cluster analysis refer to Supplemental Method
section).25 We examined the association between the two identified clusters and the risk of
pancreatic cancer using conditional logistic regression.
For the oral pathogens, we performed subgroup analyses to assess possible effect
modifications by smoking status and age (median, 62 years); tests for interaction were
conducted by including a product term of the antibodies by smoking and age in the
regression models. In sensitivity analyses, we removed the first two years of follow-up after
blood collection to address reverse causality, and separately, removed diabetics for the
analysis as these individuals are at higher risk for periodontal disease. For these sub-
analyses we used unconditional logistic regression to retain power.
All statistical analyses were conducted using the Statistical Analysis System (SAS) software
package, Version 9.2 (SAS Institute Inc., Cary, North Carolina, USA) except for the cluster
analysis which was conducted in R (using RStudio, Inc., Version 0.94.110).
RESULTS
Age at blood collection and sex were similar for cases and controls (controls were matched
to cases on these factors). Mean follow-up time was 5.0 years for cases (from time of blood
draw until date of diagnosis); controls had to be alive and free of cancer at the time the
matched case was diagnosed. Cases were more likely to be current smokers or diabetics than
controls, and had slightly higher body mass indexes (BMI; Table 1). Alcohol intake and
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height were similar among cases and controls (Table 1). Characteristics among cases who
gave blood were similar to overall pancreatic cancer cases in the EPIC cohort (blood cases
vs. total cases26: e.g., diabetes 7.0% vs 7.1%; BMI 26.7 vs 26.2; males 48% vs 40%; age
57.8 vs 58.1); although current smoking was somewhat higher in this study (30% blood
cases vs 25% all cases).
Plasma antibody detection against 25 oral bacteria was performed. Very high correlations
were observed for the two strains of P. gingivalis (ATTC strains 33277 and 53978, r=0.91),
and A. actinomycetemcomitans (ATTC strains 29523 and 43718, r=0.94). A high correlation
was also noted for the two species of Veillonella tested (Veillonella atypica and Veillonella
parvula, r=0.88); those species are relatively genetically distant.27 Most antibodies were
correlated to each other, although strength of correlations varied (Supplemental Table 2).
High antibodies levels (>200ng/ml) of P. gingivalis ATTC 53978 were more common in
cases than controls (p=0.05, Table 2), but not for the other P. gingivalis strain.
Given our a priori hypothesis that periodontal pathogens are associated with higher risk for
pancreatic cancer, we examined individual antibodies to those bacteria which have been
previously associated with periodontal tissue destruction, which include P. gingivalis, A.
actinomycetemcomitans and Tannerella forsythia (i.e., five pathogens in our assay). Of
these, the highest concentration of P. gingivalis ATTC 53978 (>200 ng/ml) was associated
with a two fold increase risk of pancreatic cancer (OR = 2.14, 95% CI = 1.05–4.36,
compared with levels <200 ng/ml; Table 3). The association was similar after removing
cases that were diagnosed within two years of blood collection, although it was no longer
statistically significant (Table 3). Adding a five year or seven year lag did not weaken the
association with P. gingivalis, if anything the association became stronger over time (OR =
2.56, 95% CI = 0.75–8.7 for the seven year lag). Furthermore, associations were positive for
all three categories of smoking status (never: OR = 2.1, 95% CI = 0.9–4.9; former: OR =
3.2, 95% CI = 0.5–21; current: OR = 2.2, 95% CI = 0.5–9.4), or after removing diabetics
(OR = 1.7, 95% CI = 0.9–3.1). Tests for interaction for smoking, age and diabetes were not
statistically significant. No associations were observed for the five oral pathogens when
using four categories of antibody levels (Supplemental Table 3).
Given our lack of a priori hypothesis on individual oral bacteria that are not considered oral
pathogens, and given the high correlations observed between these bacteria, we performed
clustering analysis to aggregate individuals depending on their antibody profiles. Two
clusters were retained for analysis based on the model with the lowest BIC score (see
Supplemental Methods for more details on cluster analysis). A strong statistically significant
inverse association was observed cluster 2 which identified individuals with consistently
higher levels of commensal oral bacteria antibodies (Table 4) compared with cluster 1
(correlations between individual bacteria and clusters are provided in Supplement Table 4).
In addition, frequencies for individual commensal oral bacteria by four categories of
antibody levels are provided in Supplemental Table 3; the majority of these associations
were inverse, indicating that antibodies to commensal bacteria are higher in controls than
cases.
DISCUSSION
We observed a 2-fold increase in pancreatic cancer among individuals who had high levels
(>200 ng/ml) of antibodies to the periodontal pathogen P. gingivalis ATTC 53978 compared
with those with lower levels (≤200 ng/ml). In addition, we noted that individuals with
consistently high levels of antibodies to common oral bacteria had a 45% lower risk of
pancreatic cancer compared to those with a profile of lower antibody levels. Antibodies
were measured in blood samples that were collected up to 10 years prior to cancer diagnosis,
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thereby most likely minimizing changes in immune response that could have occurred after
pancreatic cancer development.
A recent study reported an association between microbiota and pancreatic cancer using
saliva specimens collected after cancer diagnosis and comparing them to healthy controls
(retrospective case-control study).18 In this study, microbiota from 10 pancreatic cancer
cases were compared to 10 healthy controls, and validated in 28 independent pancreatic
cancer cases and 28 healthy controls. Two bacteria, Neisseria elongata and Streptococcus
mitis, were found to be lower in cases than controls in both datasets. These findings are
similar to ours as we also observed an inverse association with S. mitis (we did not measure
N. elongata). Our results, however, suggest that it may be more than one or two commensal
bacteria that are inversely associated with risk of pancreatic cancer.
Despite a high correlation between the two Porphyromonas strains measured in this study
(r=0.91), high levels of antibodies to P. gingivalis ATCC 53978 (6%) were much less
prevalent than for P. gingivalis ATCC 33277 (17%). These two strains are quite distinct as
P. gingivalis ATCC 53978 has a capsule known as a major antigen associated with
pathogenicity of the strain,28 while P. gingivalis ATCC 33277 lacks this antigen and is
minimally inflammatory.29, 30 Furthermore, these two strains also have different fimbrial
and outer membrane serotypes,21, 31 and a set of common antigens shared among species
based on genomic data. The association between 19 bacterial antibodies and measured
clinical indices of oral health was examined in a large U.S. population study (the third
National Health and Nutrition Examination Survey, NHANES III).32 Of the 19 antibodies
tested, only antibody titers to P. gingivalis (mixed suspension of ATCC strains 53978 and
33277) were significantly higher in individuals with periodontitis (moderate or severe, and
separately for extensive periodontitis) compared with healthy individuals (p<0.05),32 as was
previously observed in smaller studies.33–36 High levels of antibodies to P. gingivalis ATCC
53978 may be the best antibody marker for high bacterial load and aggressive periodontal
disease, which is in agreement with the NHANES III data,32 and thus may explain why it
was the only suspected periodontal pathogen associated with an elevated risk of pancreatic
cancer.
P. gingivalis ATCC 53978 levels were also elevated in cluster 2 (which was inversely
associated with risk of pancreatic cancer), as most of the other tested bacterial target were
elevated in this cluster. In adults, prevalence of P. gingivalis in subgingival plaques of
patients with periondontitis has been found to be higher than in individuals with healthy
gums.36, 37 While P. gingivalis bacterial load is strongly associated with periodontal pocket
depth, prevalence is otherwise similar between patients and controls with healthy gums
indicating the normal presence of the species in health.38–40 Most recently, a study from the
Human Microbiome Project reported that certain bacterial genera thought to be composed of
pathogenic species present in periodontal disease (e.g., Aggregatibacter, Porphyromonas,
Tannerella and Treponema) were found in at least 93% of individuals with no gum disease
suggesting that these bacterial genera are also part of the normal oral microbiota and
exposed to the immune system response.41
Oral diseases originate from changes in the ecological balance of the microbiota,35, 42, 43
suggesting that there is a beneficial effect of members of the oral microbiota.
Capnocytophaga ochracea, for example, was significantly more prevalent among healthy
patients (>90%) than chronic periodontitis patients (<60%), and was found at more sites
among healthy individuals.38 In addition, this microbe has been associated with significantly
less disease progression in other studies.44, 45 Veillonella species were, in another study,
associated with periodontal health.42 We therefore propose that the inverse associations
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observed in our study for cluster 2 may reflect individuals with oral microbial stability,
healthy gum status, and a strong immune response toward bacteria.
Host genetic susceptibility related to immune function could explain our observations.
Recent data from Genome-Wide Association Studies (GWAS) examining genetic
susceptibility and pancreatic cancer risk reported that individuals with non-O blood groups
had a higher risk of pancreatic cancer than those with blood type O.46 Although it is not
clear how these findings translate to carcinogenesis, SNPs at the ABO gene locus were
found to be determinants of circulating levels of molecules that are important mediators of
chronic inflammation and immune cell recruitment.47–50 The best-established connection
between local inflammation and pancreatic cancer comes from studies on chronic
pancreatitis.51 It has been proposed that the prolonged inflammation observed in chronic
pancreatitis patients is what initiates or aids the progression of a pancreatic tumor.52 Culture
based studied of pancreatitis have shown a bacterial colonization of the tissues.8–10
Genetic determinants of immune surveillance clearly play a critical role in pancreatic cancer
development. Consequently, it is plausible that elevated levels of antibodies to oral bacteria
in individuals serve as a marker for a genetically stronger immune response, providing
protection against carcinogenesis. In a study of periodontal disease and cancer among twins,
the associations with periodontal disease could be partially explained by shared genetic risk
factors.4 As periodontitis is a complex disease of polymicrobial origins which is influenced
by genetic susceptibility, host response and environmental factors, deciphering the genetic
component of the disease is still under study.35, 53–55
The strength of this study includes a large sample size, prediagnostic bloods, and a
methodology that enabled us to measure a large number of antibodies using small volumes
of plasma (as these are valuable resources). By using prediagnostic bloods, we were able to
minimize reverse causation, and examine the association with antibodies many years prior to
diagnosis of cancer. With 405 cases and 416 controls, we had adequate power to examine a
large number of antibodies. Furthermore, we had detailed data on smoking history and other
known risk factors of pancreatic cancer and conducted multivariate analyses to rule out
potential confounding by these factors.
The two main limitations of this study were lack of gold standard measurements for the
antibodies and having only one blood measure per subject at one point in time. We could not
conduct ELISA tests to measure antibodies, which are considered the gold standard
measurement, because we did not have sufficient blood volume in the EPIC samples;
however, the methods we used have been validated in previous studies where blood product
amounts were not a limiting factor. While we only had one measurement per individual,
antibodies to periodontal pathogens have been shown to be fairly stable over time,33, 56
which suggests that our findings would be similar if we had more than one measurement
over time. Another limitation of this study was that we did not have any data on drug use
(e.g., antibiotics or NSAID use) that may have influenced bacteria antibody levels.
Similarly, we were not able to control for chronic pancreatitis as these outcomes were not
ascertained in the EPIC cohort; it is plausible that the association observed is mediated
through pancreatitis, in which case we would not want to control for this factor. More
research is needed to examine the pathways and mechanisms that may explain our findings.
In summary, this is the first study to examine antibodies to oral bacteria and risk of
pancreatic cancer. Our findings suggest that individuals who have high levels of antibodies
to P. gingivalis ATTC 53978, a bacterium strongly associated with periodontal tissue
destruction, are at higher risk of pancreatic cancer, while a distinct cluster of individuals
with elevated antibodies to oral bacteria were associated with a lower risk of pancreatic
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cancer. Given that this is the first study to examine these associations, they will need to be
confirmed in other studies. If confirmed, our findings may open new avenues to
investigating the role of the oral bacteria and periodontal disease in pancreatic
carcinogenesis and provide exciting opportunities to improve our understanding of the
development of this fatal disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What is already known about this subject
• Pancreatitis increases the risk of pancreatic cancer
• Bacteria can disseminate into the pancreas
• Periodontal disease has been associated with pancreatic cancer
What are the new findings
• First study to prospectively examine the relationship between oral bacteria and
pancreatic cancer risk
• Porphyromonas gingivalis, a periodontal pathogen, may increase pancreatic
cancer
• Oral commensal bacteria may decrease risk of pancreatic cancer
How might it impact on clinical practice in the foreseeable future?
• Provide opportunity to better understand which bacteria are related to risk of
pancreatic cancer can lead to improvement in early detection of disease
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Table 1
Characteristics of pancreatic cancer cases and control subjects selected from the EPIC cohort for this analysis.
Cases Controls P-values*
Numbers 405 416
Males (%) 48.4 47.8
Mean (SD) age at blood collection (y) 57.8 (8.0) 57.8 (7.9)
Smoking status (%) 0.09
  Never 36.4 43.0
  Past 32.4 34.4
  Current 30.0 21.4
  Unknown 1.2 1.2
Mean (SD) BMI (kg/m2) 26.7 (4.3) 25.9 (3.9) 0.01
Mean (SD) height (cm) 168.5 (9.1) 168.2 (9.9) 0.43
Mean (SD) waist circumference (cm) 90.2 (12.5) 88.8 (12.9) 0.11
Mean (SD) alcohol at baseline (g/d) 15.8 (22.2) 15.1 (24.0) 0.88
Diabetes (%) 7.0 4.6 0.17
Postmenopausal (%, among women) 70.3 73.3 0.40
*
Paired t-test for categorical variables and McNemar’s test for continuous variables; p-values for variables that were used to match cases and
controls are not shown (i.e., sex, age, length of follow-up).
Gut. Author manuscript; available in PMC 2014 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Michaud et al. Page 15
Table 2
Percentage of samples with oral bacteria levels above 200 ng/ml by case and control subjects.
Bacteria Cases
% with IgG
levels
>200 ng/ml
Controls
% with IgG
levels
>200 ng/ml
P-value*
Oral pathogens**
(Gram negative)
  Porphyromonas gingivalis   ATCC 33277 17.3 17.3 1.0
  Porphyromonas gingivalis
  ATCC 53978
7.2 4.6 0.05
  Aggregatibacter actinomycetemcomitans
  ATCC 29523
19.8 21.9 0.45
  Aggregatibacter actinomycetemcomitans
  ATCC 43718
20.0 23.8 0.15
  Tannerella forsythia ATCC 43037 2.2 2.2 1.0
Oral bacterial species of the human
microbiome
(Gram negative)
  Captonocytophaga ochracea
  ATCC 33596
30.9 31.3 0.82
  Eikenella corrodens ATCC 23834 10.6 12.7 0.31
  Fusobacterium nucleatum ATCC 25586 4.4 4.6 0.86
  Fusobacterium periodonticum
  ATCC 33693
0.49 0.24 0.56
  Fusobacterium polymorphum
  ATCC 10953
0.25 0.24 1.0
  Prevotella intermedia ATCC 25611 4.7 4.6 0.86
  Prevotella melaninogenica ATCC 25845 10.6 11.5 0.51
  Prevotella nigrescens ATCC 33563 10.4 12.0 0.30
  Veillonella atypica ATCC 17744 0.25 0.25 1.0
  Veillonella parvula ATCC 10790 1.0 1.9 0.25
Oral bacterial species of the human
microbiome
(Gram positive)
  Actinomyces naeslundii ATCC 12104 77.5 80.5 0.22
  Bifidobacterium dentium ATCC 27534 0.99 0.48 0.41
  Corynebacterium matruchotii
  ATCC 14266
0.74 1.9 0.13
  Enterococcus faecalis ATCC 29212 0.25 0.75 0.32
  Finegoldia magna ATCC 29328 0.25 0
  Parvimonas micra ATCC 33270 47.2 52.2 0.09
  Peptostreptococcus anaerobius
  ATCC 27337
0 0
  Streptococcus intermedius ATCC 27335 5.4 5.8 0.86
  Streptococcus mitis ATCC 49456 43.7 46.9 0.25
  Streptococcus salivarius ATCC 7073 10.6 11.3 0.69
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*
McNemar’s test.
**Oral bacterial pathogens which have been previously associated with periodontal disease.
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Table 3
Odds ratios (OR) and 95% confidence intervals (CI) for pancreatic cancer associated with antibody levels to P.
gingivalis ATTC 53978.
Antibody level to
P. gingivalis ATTC 53978 Case / Controls OR (95% CI)* MV OR (95% CI )**
  Low levels (≤200ng/ml) 376/397 1.0 (referent) 1.0 (referent)
  High levels (>200 ng/ml) 29/19 2.00 (1.00–4.00) 2.14 (1.05–4.36)
Removing cases diagnosed
within 2 yrs of blood
collection
  Low levels (≤200ng/ml) 304/397 1.0 (referent) 1.0 (referent)
  High levels (>200 ng/ml) 25/19 2.10 (0.99–4.46) 2.11 (0.97–4.59)
*Odds ratios (OR) and 95% confidence intervals (CI) were obtained using conditional logistic regression (cases were matched to controls on
center, sex, follow-up time, age at blood collection, date and time of blood collection, fasting status and use of exogenous hormones among
women).
**
Multivariate odd ratios (MV OR) were obtained using conditional logistic regression and additionally adjusting for BMI (continuous) and
smoking status (never, past, current).
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Table 4
Odds ratios (OR) and 95% confidence intervals (CI) for pancreatic cancer associated with two profiles of
antibody response (clusters 1 and 2).
Cluster* Case / Controls MV OR (95% CI )**
1 Low antibody levels to
commensal oral bacteria 192/229 1.0 (referent)
2 High antibody levels to
commensal oral bacteria 212/187 0.55 (0.36–0.83)
*
For more details on cluster analysis approach, refer to Supplemental Methods.
**Odds ratios (OR) and 95% confidence intervals (CI) were obtained using conditional logistic regression (cases were matched to controls on
center, sex, follow-up time, age at blood collection, date and time of blood collection, fasting status and use of exogenous hormones among
women) and adjusting for BMI and smoking status.
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